Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts

Evan J. Brettrager, Robert C.A.M. van Waardenburg

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA.

Correspondence to: Dr. Robert C.A.M. van Waardenburg, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 155 Volker Hall, 1670 University Boulevard, Birmingham, AL 35294-0019, USA. E-mail: rvanwaar@uab.edu

How to cite this article: Brettrager EJ, van Waardenburg RCAM. Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts. Cancer Drug Resist 2019;2:1153-63. http://dx.doi.org/10.20517/cdr.2019.91

Received: 5 Oct 2019  First Decision: 19 Nov 2019  Revised: 19 Nov 2019  Accepted: 29 Nov 2019  Published: 19 Dec 2019

Science Editor: Frits Peters  Copy Editor: Jing-Wen Zhang  Production Editor: Tian Zhang

Abstract

Our genomic DNA is under constant assault from endogenous and exogenous sources, which needs to be resolved to maintain cellular homeostasis. The eukaryotic DNA repair enzyme Tyrosyl-DNA phosphodiesterase I (Tdp1) catalyzes the hydrolysis of phosphodiester bonds that covalently link adducts to DNA-ends. Tdp1 utilizes two catalytic histidines to resolve a growing list of DNA-adducts. These DNA-adducts can be divided into two groups: small adducts, including oxidized nucleotides, RNA, and non-canonical nucleoside analogs, and large adducts, such as (drug-stabilized) topoisomerase- DNA covalent complexes or failed Schiff base reactions as occur between PARP1 and DNA. Many Tdp1 substrates are generated by chemotherapeutics linking Tdp1 to cancer drug resistance, making a compelling argument to develop small molecules that target Tdp1 as potential novel therapeutic agents. Tdp1's unique catalytic cycle, which is centered on the formation of Tdp1-DNA covalent reaction intermediate, allows for two principally different targeting strategies: (1) catalytic inhibition of Tdp1 catalysis to prevent Tdp1-mediated repair of DNA-adducts that enhances the effectivity of chemotherapeutics; and (2) poisoning of Tdp1 by stabilization of the Tdp1- DNA covalent reaction intermediate, which would increase the half-life of a potentially toxic DNA-adduct by preventing its resolution, analogous to topoisomerase targeted poisons such as topotecan or etoposide. The catalytic Tdp1 mutant that forms the molecular basis of the autosomal recessive neurodegenerative disease spinocerebellar ataxia with axonal neuropathy best illustrates this concept; however, no small molecules have been reported for this strategy. Herein, we concisely discuss the development of Tdp1 catalytic inhibitors and their results.

Keywords: Tdp1, small molecules, DNA topoisomerases, Camptothecins, oxidative DNA damage, DNA adducts, Etoposide, chain terminating nucleotides/nucleoside analogs, DNA metabolism, drug development

© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
INTRODUCTION

Tyrosyl-DNA phosphodiesterase I (Tdp1) is a eukaryotic DNA repair enzyme which is a member of the phospholipase D superfamily and hydrolyzes the phosphodiester bond that links an adduct to the end of a nicked DNA strand\(^1\)-\(^3\). Tdp1 was discovered as an enzyme activity able to hydrolyze a 3' phosphotyrosyl linkage, which is the chemical bond between the active site tyrosine of Tyrosine-recombinases and eukaryotic DNA Topoisomerase I (Topo1), and the 3' phosphoryl-end of a DNA strand\(^3\). Over the last two decades, a broad spectrum of phosphodiester linked 3' and 5' DNA-adducts were identified as Tdp1 substrates\(^4\). Tdp1 natural substrates can be divided into two groups: small adducts consisting of damaged nucleotides, DNA inserted ribonucleotides, and non-canonical nucleotide/nucleoside analogs, and large adducts including covalent protein-DNA adducts that are generated as a transient reaction intermediate by, for example, DNA topoisomerases and Tdp1, or protein fragments (peptides) as a result of failed Schiff base linked proteins such as proteolytically processed poly (ADP-ribose) polymerase 1 (PARP1)-DNA adducts [Table 1]. These transient protein-DNA adducts can be stabilized by chemotherapeutics including camptothecins (CPT), epipodophyllotoxins (e.g., etoposide), and local DNA perturbations introduced by, for example, irradiation and endogenously generated reactive oxygen species [Table 1]. Moreover, Tdp1 is localized in both the nuclear and mitochondrial compartments to catalyze the hydrolysis of phosphodiester linked DNA adducts\(^4\)-\(^7\). This reveals the general role of Tdp1 in maintaining nuclear and mitochondrial genome stability and chemotherapeutic-resistance.

Tdp1 utilizes two highly conserved histidine-lysine-aspartate (HxKx,D; x being any amino acid) motifs in two coordinated S\(_\text{N2}\) nucleophilic attacks to hydrolyze the phosphodiester linkage. First, His263 nucleophilically attacks the phosphodiester bond to release the adduct/protein by forming a transient Tdp1-DNA adduct, which is broken by the general acid/base His493 mediated hydrolysis via activation of water releasing Tdp1 from the DNA-end [Figure 1]\(^2,3,11,16,26,28,31,32\). The intriguing fact is that cells risk the formation of second potentially toxic enzyme-DNA reaction intermediate to resolve the primary toxic insult. This potential danger to the cell is highlighted by the catalytic human Tdp1 (H493R) mutant, which is the molecular basis for the rare autosomal recessive neurodegenerative disease spinocerebellar ataxia with axonal neuropathy (SCAN1)\(^29,33\). Tdp1 is expressed in all human tissues at a low level, probably due to its potential danger. However, elevated levels of Tdp1 are detected in a heterologous distribution in virtually all tumors\(^7,24\). Elevated Tdp1 levels stimulate chromosome instability\(^35\) and increase cell sensitivity to DNA damaging agents\(^34,24,26,35\). Thought-provoking is that deletion of Tdp1 in yeast, DT40 chicken cells, HEK293 cells, and mice also results in enhanced cell sensitivity to DNA damaging agents\(^34,24,26,35-37\). Overall, this supports the two different therapeutic strategies hypothesized: (1) no Tdp1 activity or catalytic inhibition of Tdp1 that prevents repair of DNA-adducts leads to cytotoxicity; and (2) accumulation of Tdp1-DNA adducts via poisoning/stabilization of the protein-DNA complex, or increase of Tdp1 levels, results in cytotoxicity [Figure 1]. This review focuses on the current development of Tdp1 as a therapeutic target to improve treatment response with FDA approved chemotherapeutics - a topoisomerase targeting drug\(^30\).

TDP1 AS THERAPEUTIC TARGET

The potential of Tdp1 as a therapeutic target for catalytic inhibitors was directly proposed by Nash and co-workers in its discovery paper\(^3\). Over the last five years, the search for Tdp1 inhibitors has been rapidly growing with the therapeutic focus to combine catalytic Tdp1 inhibiting agents with the current FDA-approved Topo1 targeting chemotherapeutics. Besides catalytic inhibition, we champion a second strategy to poison Tdp1 or to pharmacologically stabilize the enzyme-DNA adduct turning Tdp1 into a cellular toxin, similar to topoisomerase inhibitors\(^4,30\). The principle of this strategy is supported by the SCAN1 His\(^60\)Arg-mutant and other Tdp1 catalytic mutants tested\(^33,31,32,36,37,41\). Currently, no small molecules for this strategy have been reported and, herein, we focus only on catalytic Tdp1 inhibitors.
To date, many catalytic Tdp1 inhibitors have been identified, yet only a few were tested in cell or cancer models. Interestingly, many of these Tdp1 catalytic inhibitors are based on natural products isolated from fungi, plants, nucleoside analogs, and bile acids showing inhibition in the low micromolar to the high nanomolar range. The first reported catalytic Tdp1 inhibitors were the non-specific transition metals vanadate ($\text{VO}_4^{3-}$) and tungstate at millimolar concentrations and were used to resolve the crystal structure of the transition state complex of hTdp1 catalytic core domain with $\text{VO}_4^-$-DNA-hTopo1 peptide fragments [42-44]. Vanadate and tungstate are known general inhibitors for protein phosphotyrosyl phosphatases [45]. Yves Pommier and collaborators advanced the search for catalytic inhibitors by exploring existing compounds and developing in vitro/alpha-screen based high-throughput screens (HTSs) using oligonucleotides with a 3' phospho-linked fluorescent adduct to mimic the 3' phospho-tyrosyl bond. They exploited antibiotic ribosomal inhibitors and identified as the first pharmacological active Tdp1 inhibitors Neomycin, an aminoglycoside analog, and non-aminoglycosides such as puromycin and thiostrepton with IC$_{50}$ ranging 2-30 mmol/L [46]. They further identified rolitetracycline and potentially other tetracycline analogs to inhibit Tdp1 catalysis at micromolar levels [47]. Huang et al. [48] successfully translated this observation by repurposing minocycline in combination with irinotecan to treat high grade ovarian cancer cell lines and an orthotopic xenograft mouse model of human ovarian carcinomatosis. Intriguingly, minocycline decreased Tdp1 expression levels that enhanced irinotecan toxicity in platinum resistant cell lines, while in vivo this combination reduced micro-metastases to improve overall survival. Why minocycline specifically reduces Tdp1 protein levels and/or inhibits Tdp1 activity as suggested for another tetracycline analog - rolitetracycline - is currently unknown [47,48]. How tetracyclines inhibit eukaryotic protein synthesis is still questionable - the most popular explanation is ribosome inhibition [49], but the reduction of one protein (Tdp1) by minocycline remains an enigma.

The diamidine analogue furamidine [2,5-bis (4-amidinophenyl) furan] was the first inhibitor identified in a HTS at National Institutes of Health (NIH) [50]. Furamidine is used to treat Trypanosomiasis and leishmaniasis, which express Tdp1, but it is unclear if Tdp1 inhibition is part of the antiparasitic activity [51]. An interesting twist is that furamidine combined with irinotecan suppresses murine lupus nephritis [52]. Additional HTSs at NIH identified additional micromolar to high nanomolar Tdp1 inhibitors: progesterone derivative NSC88915 (3,20-dioxopregn-4-en-21-yl 4-bromobenzenesulfonate) and phospho-tyrosyl mimetics such as suramin and dphostatin derivative methyl-3,4-dephostatin (3,4-Dihydroxy-N-methyl-N-nitrosoaniline) [53,54]. The Pommier and Wang collaboration identified arylidene thioazolidinone derivatives as high nanomolar inhibitors of Tdp1 catalysis [55].

The identification of non-hydrolysable phospho-tyrosyl mimetics that perfectly docked in the catalytic pocket led to the first in silico-docking screen to classify 46 additional potential Tdp1 inhibitors that dock
the catalytic cavities [Figure 2], as such competing with Tdp1 substrates\textsuperscript{[56]}. However, these compounds were not verified for their potential biochemical and biological activity. Subsequent in silico-docking screens by other groups did verify their compounds; Gushchina et al.\textsuperscript{[57]} found thioether sulfo-heterocyclic linked compounds that dock into the catalytic pocket and inhibited catalysis in the high micromolar range. Waugh's group recently reported an impressive crystallographic verification of 11 phthalic acids and quinolone-based fragment ligands identified in their in silico-docking screen\textsuperscript{[58]}. They demonstrated in silico docking within Tdp1 catalytic pocket, inhibition of Tdp1 catalysis in the mid micromolar to high millimolar range, and resolved 11 independent crystal structures of the Tdp1 catalytic domain in complex with these compounds to confirm their in silico-docking screen results, concluding they identified competitive Tdp1 inhibitors\textsuperscript{[58]}. This approach provides a great basis for structure-based drug design to further develop these inhibitors and test them in cell-based/mice models. However, except for furamidine and minocycline, none of these compounds were verified in cell-based or animal models of cancer. The first report using cell-based screens for Tdp1 inhibitors exploited Tdp1-deficient DT40 chicken cells complemented with and without human TDP1 to identify compounds that demonstrate a synergistic effect with CPT\textsuperscript{[22]}. This approach, however, identified PARP1 inhibitors and not Tdp1 inhibitors. The authors identified five compounds after a primary (DT40tdp1\textsuperscript{-/-} + hTDP1) and secondary (DT40tdp1\textsuperscript{-/-} vs. DT40tdp1\textsuperscript{-/-} + hTDP1) screen that did not show Tdp1 inhibition but inhibited PARP1-activity analyzed by ELISA and immunoblotting for PARylation. Moreover, this revealed how tricky cell-based screens and the tight cellular interplay of DNA repair-DNA damage response proteins are. This tight interplay can also foster alternative treatment strategies. For example, Pfeifer and collaborators reasoned that Tdp1 inhibitors will be synergistic with CPT but also with PARP1 inhibitors\textsuperscript{[34]}. This is mechanistically supported by the reported observation that Tdp1 and PARP1 are epistatic for the repair of Topo1-DNA adducts\textsuperscript{[9,59]}. They identified an alkylidene barbiturate derivative [CD00509; 5-\textsuperscript{(2-Furylmethylidene)-2-thioxohexahydropyrimidine-4,6-dione}] in a biochemical-screen and verified this compound in TDP1 and tdp1\textsuperscript{-/-} MEF-cells, showing that TDP1-MEFs with CD00509 showed a similar CPT sensitivity as tdp1\textsuperscript{-/-} MEFs without CD00509. Moreover, CD00509 combined with CPT or Rucaparib in MCF7 breast cancer cells resulted in more toxicity for both combinations compared to the agent alone\textsuperscript{[34]}. Thus, Tdp1 inhibition together with PARP1 inhibition is a successful treatment strategy taking advantage of additional impeding mutations that cancer cells maintain. Current knowledge adds an additional explanation: PARP1 inhibitors not only inhibit PARP1 catalysis but also stabilize the PARP1-DNA intermediate\textsuperscript{[60]}, the reaction intermediate of a Schiff base reaction, which itself induces cytotoxicity.
Moreover, the phosphodiester bond linking the damaged nucleotide to the PARP1 peptide is a substrate for Tdp1 hydrolyses. Pommier teamed up with the Malhorta group and broadened cell-based screening by testing 15 newly synthesized piperidinyl sulfamide derivatives in the NCI60 cell line panel. The advantage of this NCI60 screen is that, in addition to screening for compound induced cytotoxicity, it may reveal potential cancer specificity/cell type and may reveal potential response pathways, since the NCI60 panel has been molecular characterized over the years. Moreover, the inclusion of R- and S-stereoisomers will reveal differences in biological activity, which was observed for the only compound that induced a significant cell toxicity and inhibited Tdp1 catalysis, namely piperidyl sulfamide-18 [NSC750706; (R)-Methyl 2-(N-(1-(4-fluorobenzyl)piperidin-4-yl)-N-(3-fluorophenyl) sulfamoylamino)-3-methyl butanoate], while its S-stereoisomer, NSC764209, induced no phenotype.

Another forerunner in the hunt for Tdp1 catalytic inhibitors is Olga Lavrik and her collaborators. These researchers synthesized their derivatives and evaluated the compounds in: (1) Tdp1 catalytic assay; (2) in silico docking; and (3) cell toxicity/growth inhibition studies. They identified a wide variety of chemical scaffolds that include the Benzopentathiepines derivative 2-(Dibutylamino)-N-(8-(trifluoromethyl)benzo[f]-[1,2,3,4,5]pentathiepin-6-yl)acetamide, which inhibits catalysis at high nanomolar concentrations and induces MCF7 cytotoxicity (IC₅₀ ~ 28 μmol/L) via DNA fragmentation and apoptosis. They combined a 7-hydroxycoumarin with monoterpenoid moieties resulting in 7-((1S,5R)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one that exhibits a high nanomolar catalytic inhibition (IC₅₀ = 675 ± 7 nmol/L), a MCF7 CC₅₀ of 180 nmol/L (in combination with CPT) and increased MCF7 CPT sensitivity, but had no effect on RPMI-8226 human multiple melanoma cells that maintain lower Tdp1 levels than MCF7 cells. They concluded that the induced toxicity is Tdp1-dependent; however, this would have been better supported by knockdown of Tdp1 levels, since many other different factors, including PARP1 activity, can contribute to a lack of effect/phenotype. Using the Structure-Activity Relationship of octahydro-2H-chromen-4-ol scaffold, the Lavrik group developed a series of 3(4S)- and 3(4R)-diastereomers derivative with different bulky side-groups.
that inhibit Tdp1 catalysis in the low micromolar range while in silico-docking showed that each of these six ligands binds Tdp1 in more than one location within the Tdp1 catalytic cavity [Figure 2][64]. Recently, Lavrik and colleagues reported 15 monoterpenoid and adamantane fragments, which are able to inhibit Tdp1 catalysis (0.86-4.08 μmol/L). Of these 15 fragments, 3,7-Dimethyloctyl adamantane-1-carboxylate in combination with topotecan induced synergistic toxicity in A549 human lung carcinoma cells[65].

In addition to arrays of synthesized compounds, Lavrik and co-workers also utilized natural product scaffolds in their search for potential Tdp1 catalytic inhibitors. They synthesized 29 aryliden- and hetarylidenefurane derivatives of usnic acid (a metabolite found in various lichens) that inhibit Tdp1 in the low nanomolar range. These compounds also induced A549 cytotoxicity with IC₅₀ between 5 and 20 μmol/L and potentiated topotecan toxicity[66]. Their subsequent synthesized hydrazinothiazole usnic acid derivative ((R,E)-2-acetyl-6-(2-(2-(4-bromobenzylidene)hydrazinyl)thiazol-4-yl)-3,7,9-trihydroxy-8,9b-dimethyl dibenz[b,d]furan-1(9bH)-one) is an effective Tdp1 catalytic inhibitor that increased topotecan toxicity in a Lewis lung carcinoma cell model and was the first potential Tdp1 inhibitor to show, in combination with topotecan, an anti-tumor and anti-metastatic effect in a mouse model of Lewis Lung Carcinoma[67]. This compound is now entering the preclinical trial phase. This group also used semi-synthetic derivatives of bile acids and disaccharide nucleosides as a scaffold for the development of Tdp1 catalytic inhibitors[68,69]. The bile acid derivatives were tested by in silico-docking and in a catalytic assay showing inhibition in the 300 to 500 nmol/L ranges with N-(2''-(3'',5'')-Di-tret-butyl-4'-hydroxyphenyl)ethyl)-3a,12a-diacetoxy-5b-cholan-24-amide as the most promising compound[69]. Disaccharide nucleosides were explored as Tdp1 inhibitors following reports showing that pyrimidine disaccharide derivatives including nicotinamide adenine dinucleotide (NAD')-mimetics catalytically inhibited PARP1[70] and that PARP1 synthesized free PAR-monomers and -polymers that inhibit, for example, XPC-RAD23B[71]. Disaccharide nucleoside analogs inhibited wild type Tdp1 catalysis (low micromolar to high nanomolar range) but interestingly not the Tdp1H493R-SCAN1-mutant[68]. Why these compounds do not show inhibition of the SCAN1-mutant enzyme is unknown and cannot be explained from the reported experimental results. However, some of these compounds potentiated topotecan induced toxicity in A549 cells and non-cancerous WI-38 (fibroblasts derived from lung tissue of a three months gestation female fetus) cells, suggesting to induce “normal” cell toxicity. These active derivatives can be divided into three classes: (1) 1'-2')-glycosidic bond (2'-O-pentafuranosyl nucleosides); (2) b(1'-3')-glycosidic bond (3'-O-b-D-ribofuranosyl nucleosides); and (3) b(1'-5')-glycosidic bond (5'-O-β-D-ribofuranosyl nucleosides). They induce catalytic inhibition in the low micromolar to high nanomolar range, but need further development[68]. Quinn and co-workers exploited 3,4-dimethoxyphenol-1-β-D-(6'-O-galloyl) glucopyranoside and 3-(4-hydroxy-3-methoxyphenyl)propane-1,2-diol2-β-D-(6-O-galloyl) glucopyranoside from Macropteranthes leichhardtii, and achyrodimer F from the teleomorphic fungus family Cortinariaceae. Both compounds inhibit Tdp1 in the low micromolar range[72,73]. Takagi et al.[74] isolated JBIR21 from an unidentified anamorphic fungus RF-13305 culture that showed catalytic inhibition with IC₅₀ of 18 μmol/L and induced growth inhibition of cervical carcinoma HeLa cells, malignant mesothelioma NCI-H2052 cells, colon adenocarcinoma HT-29 cells, and lymphoblastoid namalva cells with an IC₅₀ range of 3.5-3 μmol/L. JBIR21 also showed an antitumor effect in a HT-29 xenograft model (treatment-to-control ratio of 0.51) without noticeable toxicity or other adverse effects, suggesting that JBIR21 forms a highly potential scaffold for further development of a clinically applicable compound. Figure 3 shows examples of structures of potential Tdp1 inhibitors discussed above.

CONCLUSION

Over the last two decades, the development of Tdp1 catalytic inhibitors has produced active compounds that showed a high potential to be tested in (pre-)clinical trials. Although these compounds were originally selected for their ability to inhibit Tdp1 catalysis and modeled-docking of the compounds into the Tdp1 catalytic pocket, the more current and promising compounds were tested in combination with DNA
Topo1 inhibitors (topotecan or irinotecan) in cell and xenograft mouse models of cancer. However, Tdp1 specificity is still unclear and has not been addressed yet for all these compounds. Moreover, the potential development of Tdp1-poisons, compounds that selectively increase the lifetime of Tdp1-DNA adducts similar to Tdp1 catalytic mutants such as the SCAN1 mutant, would be a welcome addition for combinational treatment options for anti-cancer therapy. These molecules form a promising base for further development to join the fight against cancer. The development of catalytic Tdp1 inhibitors might also help patients with other diseases such as SCAN1, which appears to be a common founder mutation in the Arab population and even Lupus nephritis. Hence, the "SCAN1" Tdp1H493R mutant enzyme performs the first step [Figure 1] with similar kinetics as the wild type Tdp1. However, the rate of the second step is dramatically reduced, resulting in a prolonged life-time of the toxic enzyme-DNA covalent reaction intermediate. Thus, catalytic inhibition of this SCAN1 Tdp1 mutant would prevent the formation of the toxic Tdp1SCAN1-DNA intermediate and the subsequent induction of cerebellar atrophy, which could stabilize disease progression and symptoms.

Figure 3. Structures of potential Tdp1 inhibitors. A: Vanadate; B: Neomycin; C: Puromycin; D: Rolitetracycline; E: Minocycline; F: methyl-3,4-dephostatin; G: (R,E)-2-acetyl-6-(2-(4-bromobenzyliden)hydrazinyl)thiazole-4-yl)-3,7,9-trihydroxy-8,9b-dimethyl dibenzo[b,d]furan-1(9bH)-one; H: 7-(((15R,5R)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one; J: 3,20-Dioxopregn-4-en-21-yl 4-bromobenzensulfonate; K: 2-(Dibutylamino)-N-(8-(trifluoromethyl)benzo[1][1,2,3,4,5]pentathiepin-6-yl)acetamide; L: (R)-Methyl 2-(N-(1-(4-fluorobenzyl)piperidin-4-yl)-N-(3-fluorophenyl) sulfamoyl amino)-3-methylbutanoate; M: 5-(2-Furyl Methylidene)-2-thioxo hexahydro pyrimidine-4,6-dione. Box letters are compounds tested in vivo. Chemical structures were drawn using MarvinSketch (17.3.13.0) ChemAxon (http://www.chemaxon.com)
DECLARATIONS

Acknowledgments
We want to thank the present and past van Waardenburg lab-members and our collaborators for contributing to increase our knowledge of Tdp1 and Topoisomerases and Ms. Lisa Park for critical reading and editing of this manuscript. Our apologies to colleagues whose work we did not mention, due to space limitations. RCAMvW greatly appreciates the current and past financial support from the UAB Department of Pharmacology and Toxicology, UAB O’Neil Comprehensive Cancer center, UAB ACS-IRG Junior Faculty Development, DOD-OCRP pilot award, UAB School of Medicine, the Norma Livingston Ovarian Cancer Foundation and the Alabama Drug Discovery Alliance.

Authors’ contributions
Collected data, wrote the review and edited the revision: Brettrager EJ, van Waardenburg RCAM

Availability of data and materials
Not applicable.

Financial support and sponsorship
RCAMvW was in part funded by American Cancer Society UAB ACS-IRG Junior Faculty Development Grant (ACS-IRG-60-001-53); Department of Defense OCRP pilot award W81XWH-15-1-0198; and the National Institutes of Health Cancer Center Core Support Grant (P30CA013148).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Interthal H, Pouliot JJ, Champoux JJ. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc Natl Acad Sci U S A 2001;98:12009-14.
2. Pouliot JJ, Yao KC, Robertson CA, Nash HA. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science 1999;286:552-5.
3. Yang SW, Burgin AB Jr, Huizenga BN, Robertson CA, Yao KC, et al. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc Natl Acad Sci U S A 1996;93:11534-9.
4. Comeaux EQ, van Waardenburg RC. Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target. Drug Metab Rev 2014;46:494-507.
5. Ben Hassine S, Arcangioli B. Tdp1 protects against oxidative DNA damage in non-dividing fission yeast. EMBO J 2009;28:632-40.
6. Das BB, Dexheimer TS, Maddali K, Pommier Y. Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. Proc Natl Acad Sci U S A 2010;107:19790-5.
7. Fam HK, Chowdhury MK, Walton C, Choi K, Boerkoel CF, et al. Expression profile and mitochondrial colocalization of Tdp1 in peripheral human tissues. J Mol Histol 2013;44:481-94.
8. Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, et al. TDP1 is critical for the repair of DNA breaks induced by sapacitabine, a nucleoside also targeting ATM- and BRCA-deficient tumors. Mol Cancer Ther 2017;16:2543-51.
9. Alagoz M, Wells OS, El-Khamisy SF. TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy. Nucleic Acids Res 2014;42:3089-103.
10. Huang SY, Mural J, Dalla Rosa I, Dexheimer TS, Naumova A, et al. TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating antinecancer and antiviral nucleoside analogs. Nucleic Acids Res 2013;41:7793-803.
43. Davies DR, InteRthal H, Champoux JJ, Hol WG. Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. Chem Biol 2003;10:139-47.

44. Davies DR, InteRthal H, Champoux JJ, Hol WG. Explorations of peptide and oligonucleotide binding sites of tyrosyl-DNA phosphodiesterase using vanadate complexes. J Med Chem 2004;47:829-37.

45. Swarup G, Cohen S, Garbers DL. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Commun 1982;107:1104-9.

46. Liao Z, Thibault L, Jobson A, Pommier Y. Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors. Mol Pharm 2006;70:366-72.

47. Huang SN, Pommier Y, Marchand C. Tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibitors. Expert Opin Ther Pat 2011;21:1285-92.

48. Huang HC, Liu J, Baglo Y, Rizvi I, Anbil S, et al. Mechanism-informed repurposing of minocycline overcomes resistance to topoisomerase inhibition for peritoneal carcinomatosis. Mol Cancer Ther 2018;17:508-20.

49. Chukwudi CU. RNA binding sites and the molecular mechanism of action of the tetracyclines. Antimicrob Agents Chemother 2016;60:4433-41.

50. Antony S, Marchand C, Stephen AG, Thibault L, Agama KK, et al. Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1. Nucleic Acids Res 2007;35:4474-84.

51. Banerjee B, Roy A, Sen N, Majumder HK. A tyrosyl DNA phosphodiesterase I from kinetoplastid parasite Leishmania donovani (LdTdp1) capable of removing topo I-DNA covalent complexes. Mol Microbiol 2010;78:119-37.

52. Keil A, Frese-Schaper M, Steiner SK, Korner M, Schmid RA, et al. The Topoisomerase I inhibitor irinotecan and the Tyrosyl-DNA phosphodiesterase 1 inhibitor furamidine synergistically suppress murine lupus nephritis. Arthritis Rheumatol 2015;67:1858-67.

53. DexeRher T, Gedya LK, Stephen AG, Weidlich I, Antony S, et al. 4-Pregnen-2-10,20-diene-21-(4-bromobenzensulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. J Med Chem 2009;52:7122-31.

54. Marchand C, Lea VA, Jadav A, DexeRher TS, Austin CP, et al. Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay. Mol Cancer Ther 2009;8:2400-8.

55. Sirivolu VR, Vermeyer SK, Marchand C, Naumova A, Chergui A, et al. 5-Arylideneoxothiazolidinones as inhibitors of tyrosyl-DNA phosphodiesterase 1. J Med Chem 2012;55:8671-84.

56. Weidlich IE, DexeRher T, Marchand C, Antony S, Pommier Y, et al. Inhibitors of human tyrosyl-DNA phosphodiesterase (bTdp1) developed by virtual screening using ligand-based pharmacophores. Bioorg Med Chem 2010;18:182-9.

57. Gushchina IV, Nilov DK, Zakharenko AL, Lavrik OL, Svedas VK. Structure modeling of human Tyrosyl-DNA phosphodiesterase 1 and screening for its inhibitors. Acta Naturae 2017;9:59-66.

58. Lountos GT, Zhao XZ, Kiselev E, Tropea JE, Needle D, et al. Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase 1 (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening. Nucleic Acids Res 2019;47:10134-50.

59. Das BB, Huang SY, Murai J, Rehman I, Ame JC, et al. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res 2014;42:4435-49.

60. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, et al. Stereosepecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2013;14:433-43.

61. Jun JH, Kumar V, DexeRher TS, Weidlich I, Nicklaus MC, et al. Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides. Eur J Pharm Sci 2018;111:337-48.

62. Zakharenko A, Khomenko T, Zhukova S, Koval O, Zakharova O, et al. Synthesis and biological evaluation of novel tyrosyl-DNA phosphodiesterase 1 inhibitors with a benzopentathiepine moiety. Bioorg Med Chem 2015;23:2044-52.

63. Khomenko T, Zakharenko A, Odarchenko T, Arashahi HJ, Sannikova V, et al. New inhibitors of tyrosyl-DNA phosphodiesterase 1 (Tdp 1) combining 7-hydroxycoumarin and monoterpenoid moieties. Bioorg Med Chem 2016;24:5573-81.

64. Li-Zhulanov NS, Zakharenko AL, Chepanova AA, Patel J, Zafar A, et al. A novel class of Tyrosyl-DNA phosphodiesterase 1 inhibitors that contains the octahydro-2H-chromen-4-ol scaffold. Molecules 2018;23:E2468.

65. Mozaitsev ES, Zakharenko AL, Suslov EV, Korchagina DV, Zakharova OD, et al. Novel inhibitors of DNA repair enzyme TDP1 combining monoterpenoid and adamantane fragments. Anticancer Agents Med Chem 2019;19:463-72.

66. Zakharova O, Luzina O, Zakharenko A, Sokolov D, Filimonov A, et al. Synthesis and evaluation of aryliden- and hetarylidennfurano derivatives of usnic acid as highly potent Tdp1 inhibitors. Bioorg Med Chem 2018;26:4470-80.

67. Zakharenko AL, Luzina OA, Sokolov DN, Kaledin VI, Nikolin VP, et al. Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topotesmals es, Criciflcar on in vivo tumor models. Eur J Med Chem 2019;161:581-93.

68. Komarova AO, Drenichev MS, Dyrekheva NS, Kulikova IV, Oslovsky VE, et al. Novel group of tyrosyl-DNA phosphodiesterase 1 inhibitors based on disaccharide nucleosides as drug prototypes for anti-cancer therapy. J Enzyme Inhib Med Chem 2018;33:1415-29.

69. Salomatinova OV, Popadyuk YL, Zakharenko AL, Zakharova OD, Fadeev DS, et al. Novel semisynthetic derivatives of bile acids as effective Tyrosyl-DNA phosphodiesterase 1 inhibitors. Molecules 2018;23:E679.

70. Efremova AS, Zakharenko AL, Shram SI, Kulikova IV, Drenichev MS, et al. Disaccharide pyrimidine nucleosides and their derivatives: a novel group of cell-penetrating inhibitors of poly(ADP-ribose) polymerase 1. Nucleosides Nucleotides Nucleic Acids 2013;32:510-28.

71. Maltseva EA, Rechkunova NI, Sukhanova MV, Lavrik OI. Poly(ADP-ribose) polymerase 1 modulates interaction of the nucleotide excision repair factor XPC-RAD23B with DNA via Poly(ADP-ribose)lation. J Biol Chem 2015;290:21811-20.

72. Tian LW, Feng Y, Tran TD, Shimizu Y, Pfeifer T, et al. Tyrosyl-DNA phosphodiesterase 1 inhibitors from the Australian plant macropantheris leichhardtii. J Nat Prod 2015;78:1756-60.

73. Tian LW, Feng Y, Tran TD, Shimizu Y, Pfeifer T, et al. Achyrodimer F, a tyrosyl-DNA phosphodiesterase I inhibitor from an Australian
fungus of the family Cortinariaceae. Bioorg Med Chem Lett 2017;27:4007-10.

74. Takagi M, Ueda JY, Hwang JH, Hashimoto J, Izumikawa M, et al. Tyrosyl-DNA phosphodiesterase 1 inhibitor from an anamorphic fungus. J Nat Prod 2012;75:764-7.